Insider Buying: Peter A. Md Demopulos Acquires 6,153 Shares of Omeros Stock (OMER)
Omeros (NASDAQ:OMER) Director Peter A. Md Demopulos acquired 6,153 shares of the stock in a transaction dated Tuesday, June 24th. The stock was purchased at an average price of $16.20 per share, with a total value of $99,678.60. Following the acquisition, the director now directly owns 181,220 shares in the company, valued at approximately $2,935,764. The acquisition was disclosed in a document filed with the SEC, which is available at this link.
A number of analysts have recently weighed in on OMER shares. Analysts at Needham & Company LLC reiterated a “buy” rating on shares of Omeros in a research note on Monday, April 7th. They now have a $17.00 price target on the stock, up previously from $15.00. Analysts at WBB Securities raised their price target on shares of Omeros from $20.00 to $30.00 in a research note on Monday, April 7th. They now have a “strong-buy” rating on the stock.
Shares of Omeros (NASDAQ:OMER) traded up 4.43% during mid-day trading on Tuesday, hitting $16.04. The stock had a trading volume of 933,389 shares. Omeros has a 52-week low of $4.75 and a 52-week high of $16.80. The stock’s 50-day moving average is $12.60 and its 200-day moving average is $11.96. The company’s market cap is $543.9 million.
Omeros (NASDAQ:OMER) last issued its quarterly earnings data on Monday, May 12th. The company reported ($0.45) EPS for the quarter, meeting the Thomson Reuters consensus estimate of ($0.45). The company had revenue of $0.10 million for the quarter, compared to the consensus estimate of $0.45 million. During the same quarter in the prior year, the company posted ($0.40) earnings per share. The company’s quarterly revenue was down 90.9% on a year-over-year basis. Analysts expect that Omeros will post $-1.55 EPS for the current fiscal year.
Omeros Corporation operates as a biopharmaceutical company focused on the discovery, development and commercialization of products focused on inflammation and disorders of the central nervous system.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.